EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT
Zapytaj lekarza o receptę na EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT
Jak stosować EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT
INSTRUCTIONS for medical use of the medicinal product THIOTRIAZOLIN
Composition
active substance: thiotriazolin; 1 ml of solution contains morpholine salt of thiazothic acid (thiotriazolin) in terms of 100% substance – 10 mg; 1 ml of solution contains 20 drops; excipients: sodium chloride, methylcellulose, water for injections.
Pharmaceutical form
Eye drops.
Main physical and chemical properties
Slightly opalescent, colorless or with a slightly yellowish tint liquid.
Pharmacotherapeutic group
Ophthalmological agents. ATC code S01X A.
Pharmacological properties
Pharmacodynamics
The pharmacological effect of thiotriazolin is due to the activation of the antioxidant system of enzymes and the inhibition of lipid peroxidation processes in ischemic areas of eye tissues, reduction of the severity of neurotrophic disorders, increase in the intensity and rate of reparative processes, reduction of inflammatory reactions of tissues, improvement of blood flow in the microcirculatory bed of the eye. The preparation promotes early recovery of corneal sensitivity, formation of a more delicate haze, significant reduction of various complications, reduces manifestations of visual asthenopia, improves functional indicators of the accommodative muscle and central parts of the retina, which improves the functional ability of the eyes.
Pharmacokinetics
Not studied.
Clinical characteristics
Indications
Eye injuries and burns, inflammatory and dystrophic diseases of the cornea, viral conjunctivitis. For the prevention of eye inflammation, reduction of visual asthenopia in individuals working with personal computers.
Contraindications
Increased sensitivity to the preparation.
Interaction with other medicinal products and other types of interactions
Unknown.
Special warnings and precautions for use
None.
Use during pregnancy or breastfeeding
No contraindications.
Ability to influence the reaction rate when driving vehicles or operating other mechanisms
Does not affect.
Method of administration and dosage
The preparation is prescribed from the first days of the disease in the form of instillation of 2 drops 3-4 times a day into the conjunctival sac of the affected eye.
Instillations of Thiotriazolin are carried out for 14-15 days. If necessary, the treatment course can be extended to 30 days.
For individuals working with personal computers, the preparation is prescribed in the form of instillations of 2 drops immediately before the start of work, and then every 2 hours. The duration of application is determined individually by the doctor.
Since the preparation is stored at a temperature of 2-8 °C after opening the vial, it must be warmed to room temperature before use.
Children
There is no experience with the use of the preparation in children, so it is not recommended to prescribe the preparation to this age group of patients.
Overdose
When following the recommended doses, overdose is impossible.
Adverse reactions
Usually, the preparation is well tolerated, possible reactions at the site of administration. With increased individual sensitivity, allergic reactions are possible, including itching, hyperemia.
There have been reports of non-serious adverse events.
Shelf life
2 years.
After opening the vial, store at a temperature between 2 °C and 8 °C for 5 days.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Store in a place inaccessible to children.
Packaging
1 vial with a dropper cap in a pack.
Release category
By prescription.
Manufacturer
Joint-Stock Company "Kyivmedpreparat).
Location of the manufacturer and address of the place of business
Ukraine, 01032, Kyiv, Saksaganskogo Street, 139.
- Kraj rejestracji
- Substancja czynna
- Wymaga receptyTak
- Producent
- Te informacje mają charakter wyłącznie poglądowy i nie stanowią porady medycznej. Przed zastosowaniem jakiegokolwiek leku zawsze skonsultuj się z lekarzem. Oladoctor nie ponosi odpowiedzialności za decyzje medyczne podjęte na podstawie tych treści.
- Zamienniki EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARATPostać farmaceutyczna: tablets, 30 tablets in a containerSubstancja czynna: tenofovir disoproxil and emtricitabineProducent: ГЕТЕРО ЛАБЗ ЛІМІТЕДWymaga receptyPostać farmaceutyczna: tablets, 300mg/200mgSubstancja czynna: tenofovir disoproxil and emtricitabineProducent: Емкур Фармасьютікалс ЛтдWymaga receptyPostać farmaceutyczna: tablets, 300mg/200mg, 30 tablets in a bottleSubstancja czynna: tenofovir disoproxil and emtricitabineProducent: Маклеодс Фармасьютикалс ЛімітедWymaga recepty
Odpowiedniki EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT w innych krajach
Najlepsze odpowiedniki z tą samą substancją czynną i działaniem terapeutycznym.
Odpowiednik EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT – Hiszpania
Odpowiednik EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT – Polska
Lekarze online w sprawie EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT
Konsultacja w sprawie dawkowania, działań niepożądanych, interakcji, przeciwwskazań i odnowienia recepty na EMTRICITABIN/TENOFOVIRU DIZOPROKSILU FUMARAT – decyzja należy do lekarza, zgodnie z lokalnymi przepisami.
Zapisz się na aktualizacje
Otrzymuj informacje o nowych usługach online, zmianach i ofertach dostępnych na Oladoctor w Europie.
